ArticleFrontiers in endocrinology2025
Role of follicle-stimulating hormone receptor polymorphism in predicting ovarian response to letrozole in women with polycystic ovary syndrome during ovulation induction.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular analysis of FSHR rs6166 polymorphism and oxidative stress parameters in women with polycystic ovary syndrome.Molecular biology reports · 2026Article
- Significance of Follicle-Stimulating Hormone Receptor Gene Single-Nucleotide Polymorphism rs6165/rs6166 Analysis for Infertility-Associated Ovarian Disease Susceptibility Prediction and Optimized Individualized Ovulation Induction/Ovarian Stimulation.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Letrozole is a first-line treatment for anovulatory infertility in women with polycystic ovary syndrome (PCOS). Despite its widespread use, a significant proportion of patients exhibit non-responsive cycles, limiting treatment efficacy. Identifying predictive markers for ovarian response could enhance the efficiency and cost-effectiveness of ovulation induction. Previous studies have suggested an association between follicle-stimulating hormone receptor (FSHR) polymorphisms and ovarian response, though the precise relationship between these polymorphisms and ovarian response to letrozole remains poorly defined. Methods: This retrospective study analyzed data from 133 women with PCOS (93 responsive to letrozole and 40 resistant) between January 2021 and May 2024. Demographic data were collected, and genotyping of FSHR single nucleotide polymorphisms (c.2039A>G, rs6166 at position 680, and c.919A>G, rs6165 at position 307) was performed using predesigned TaqMan SNP assays. A binary logistic regression model was employed to evaluate the predictive value of FSHR polymorphisms in letrozole resistance. Results: The Asn/Asn polymorphism at position 680 was significantly more prevalent in the letrozole-resistant group (57.5%) compared to the letrozole-responsive group (34.41%) [OR: 1.543 (95% CI, 1.046-2.278), P = 0.013]. Similarly, the Thr/Thr polymorphism at position 307 was more common in the resistance group (57.5% vs. 30.11%) [OR: 1.645 (95% CI, 1.120-2.415), P = 0.003]. Participants with either the Asn/Asn or Thr/Thr polymorphism were more likely to exhibit resistance to letrozole. Logistic regression analysis indicated that the Asn/Asn polymorphism was a potential risk factor for letrozole resistance [OR: 5.227 (95% CI, 0.994-27.490), P = 0.051], while the Thr/Thr polymorphism significantly influenced letrozole response [OR: 7.04 (95% CI, 1.394-35.559), P = 0.018]. Conclusions: The Asn/Asn polymorphism at position 680 and the Thr/Thr polymorphism at position 307 of the FSHR gene may serve as potential predictors of ovulatory failure during letrozole therapy in PCOS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.